Hasil Pencarian - Robert T Bailer

  • Menampilkan 1 - 20 hasil dari 20
Perbaiki Hasil
  1. 1
    Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).

    Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). oleh Mary E Enama, Julie E Ledgerwood, Laura Novik, Martha C Nason, Ingelise J Gordon, LaSonji Holman, Robert T Bailer, Mario Roederer, Richard A Koup, John R Mascola, Gary J Nabel, Barney S Graham, VRC 011 Study Team

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.

    DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. oleh Barney S Graham, Mary E Enama, Martha C Nason, Ingelise J Gordon, Sheila A Peel, Julie E Ledgerwood, Sarah A Plummer, John R Mascola, Robert T Bailer, Mario Roederer, Richard A Koup, Gary J Nabel, VRC 008 Study Team

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.

    Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical... oleh Uzma N Sarwar, Laura Novik, Mary E Enama, Sarah A Plummer, Richard A Koup, Martha C Nason, Robert T Bailer, Adrian B McDermott, Mario Roederer, John R Mascola, Julie E Ledgerwood, Barney S Graham, VRC 015 study team

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

    Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity oleh James J. Steinhardt, Javier Guenaga, Hannah L. Turner, Krisha McKee, Mark K. Louder, Sijy O’Dell, Chi-I Chiang, Lin Lei, Andrey Galkin, Alexander K. Andrianov, Nicole A. Doria-Rose, Robert T. Bailer, Andrew B. Ward, John R. Mascola, Yuxing Li

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

    Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. oleh Richard A Koup, Mario Roederer, Laurie Lamoreaux, Jennifer Fischer, Laura Novik, Martha C Nason, Brenda D Larkin, Mary E Enama, Julie E Ledgerwood, Robert T Bailer, John R Mascola, Gary J Nabel, Barney S Graham, VRC 009 Study Team, VRC 010 Study Team

    Diterbitkan 2010-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).

    Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). oleh Michelle C Crank, Eleanor M P Wilson, Laura Novik, Mary E Enama, Cynthia S Hendel, Wenjuan Gu, Martha C Nason, Robert T Bailer, Gary J Nabel, Adrian B McDermott, John R Mascola, Richard A Koup, Julie E Ledgerwood, Barney S Graham, VRC012 Study Team

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.

    DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. oleh Julie E Ledgerwood, Abbie R Bellamy, Robert Belshe, David I Bernstein, Srilatha Edupuganti, Shital M Patel, Phyllis Renehan, Thad Zajdowicz, Richard Schwartz, Richard Koup, Robert T Bailer, Galina V Yamshchikov, Mary E Enama, Uzma Sarwar, Brenda Larkin, Barney S Graham, VRC 701 study team

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.

    Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in... oleh Cristina Carter, Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Grace L Chen, Shital M Patel, Patricia Winokur, Robert Belshe, Cornelia L Dekker, Barney S Graham, Julie E Ledgerwood, VRC 703 study team

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Phase 1 study of pandemic H1 DNA vaccine in healthy adults.

    Phase 1 study of pandemic H1 DNA vaccine in healthy adults. oleh Michelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, Sandra Sitar, Zonghui Hu, Mary E Enama, LaSonji A Holman, Robert T Bailer, Melissa B Pearce, Richard A Koup, John R Mascola, Gary J Nabel, Terrence M Tumpey, Richard M Schwartz, Barney S Graham, Julie E Ledgerwood, VRC 308 Study Team

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

    DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. oleh Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Myeisha Paskel, Kanta Subbarao, Edwin Anderson, David I Bernstein, Buddy Creech, Harry Keyserling, Paul Spearman, Peter F Wright, Barney S Graham, Julie E Ledgerwood, VRC 702 study team

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

    Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry oleh Yen-Ting Lai, Tao Wang, Sijy O’Dell, Mark K. Louder, Arne Schön, Crystal S. F. Cheung, Gwo-Yu Chuang, Aliaksandr Druz, Bob Lin, Krisha McKee, Dongjun Peng, Yongping Yang, Baoshan Zhang, Alon Herschhorn, Joseph Sodroski, Robert T. Bailer, Nicole A. Doria-Rose, John R. Mascola, David R. Langley, Peter D. Kwong

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

    An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial oleh Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.

    Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. oleh Nicole A Doria-Rose, Han R Altae-Tran, Ryan S Roark, Stephen D Schmidt, Matthew S Sutton, Mark K Louder, Gwo-Yu Chuang, Robert T Bailer, Valerie Cortez, Rui Kong, Krisha McKee, Sijy O'Dell, Felicia Wang, Salim S Abdool Karim, James M Binley, Mark Connors, Barton F Haynes, Malcolm A Martin, David C Montefiori, Lynn Morris, Julie Overbaugh, Peter D Kwong, John R Mascola, Ivelin S Georgiev

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

    Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adult... oleh Kenneth H Mayer, Kelly E Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E Ledgerwood, Ian Frank, Magdalena E Sobieszczyk, Lindsey R Baden, Benigno Rodriguez, Hong Van Tieu, Georgia D Tomaras, Aaron Deal, Derrick Goodman, Robert T Bailer, Guido Ferrari, Ryan Jensen, John Hural, Barney S Graham, John R Mascola, Lawrence Corey, David C Montefiori, HVTN 104 Protocol Team, and the NIAID HIV Vaccine Trials Network

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

    Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. oleh Walter Jaoko, Etienne Karita, Kayitesi Kayitenkore, Gloria Omosa-Manyonyi, Susan Allen, Soe Than, Elizabeth M Adams, Barney S Graham, Richard A Koup, Robert T Bailer, Carol Smith, Len Dally, Bashir Farah, Omu Anzala, Claude M Muvunyi, Jean Bizimana, Tony Tarragona-Fiol, Philip J Bergin, Peter Hayes, Martin Ho, Kelley Loughran, Wendy Komaroff, Gwynneth Stevens, Helen Thomson, Mark J Boaz, Josephine H Cox, Claudia Schmidt, Jill Gilmour, Gary J Nabel, Patricia Fast, Job Bwayo

    Diterbitkan 2010-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

    Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. oleh Susan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, Nicos Karasavvas, Raphael Gottardo, Constance Williams, Daryl E Morris, Georgia Tomaras, Mangala Rao, Erik Billings, Phillip Berman, Xiaoying Shen, Charla Andrews, Robert J O'Connell, Viseth Ngauy, Sorachai Nitayaphan, Mark de Souza, Bette Korber, Richard Koup, Robert T Bailer, John R Mascola, Abraham Pinter, David Montefiori, Barton F Haynes, Merlin L Robb, Supachai Rerks-Ngarm, Nelson L Michael, Peter B Gilbert, Jerome H Kim

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

    Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. oleh Martin R Gaudinski, Emily E Coates, Katherine V Houser, Grace L Chen, Galina Yamshchikov, Jamie G Saunders, LaSonji A Holman, Ingelise Gordon, Sarah Plummer, Cynthia S Hendel, Michelle Conan-Cibotti, Margarita Gomez Lorenzo, Sandra Sitar, Kevin Carlton, Carolyn Laurencot, Robert T Bailer, Sandeep Narpala, Adrian B McDermott, Aryan M Namboodiri, Janardan P Pandey, Richard M Schwartz, Zonghui Hu, Richard A Koup, Edmund Capparelli, Barney S Graham, John R Mascola, Julie E Ledgerwood, VRC 606 Study Team

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

    Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. oleh Raphael Gottardo, Robert T Bailer, Bette T Korber, S Gnanakaran, Joshua Phillips, Xiaoying Shen, Georgia D Tomaras, Ellen Turk, Gregory Imholte, Larry Eckler, Holger Wenschuh, Johannes Zerweck, Kelli Greene, Hongmei Gao, Phillip W Berman, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Merlin L Robb, Nelson L Michael, Jerome H Kim, Susan Zolla-Pazner, Barton F Haynes, John R Mascola, Steve Self, Peter Gilbert, David C Montefiori

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

    Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody oleh Young D. Kwon, Gwo-Yu Chuang, Baoshan Zhang, Robert T. Bailer, Nicole A. Doria-Rose, Tatyana S. Gindin, Bob Lin, Mark K. Louder, Krisha McKee, Sijy O’Dell, Amarendra Pegu, Stephen D. Schmidt, Mangaiarkarasi Asokan, Xuejun Chen, Misook Choe, Ivelin S. Georgiev, Vivian Jin, Marie Pancera, Reda Rawi, Keyun Wang, Rajoshi Chaudhuri, Lisa A. Kueltzo, Slobodanka D. Manceva, John-Paul Todd, Diana G. Scorpio, Mikyung Kim, Ellis L. Reinherz, Kshitij Wagh, Bette M. Korber, Mark Connors, Lawrence Shapiro, John R. Mascola, Peter D. Kwong

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

    Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials oleh Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: